市場調查報告書
商品編碼
1159350
白血病治療藥的全球市場(2022年~2028年)Leukemia Therapeutic Market 2022-2028 |
全球白血病治療藥的市場規模,在預測期間內預計以7.3%的大幅度年複合成長率成長。推動全球白血病治療藥市場成長的顯著要素,是活用各種治療方法日益進步的癌症治療中,以需求與未滿足的醫療需求為焦點。再加上研究開發的支出增加,對生活品質優勢的關注高漲,政府對醫療的投資增加,為了強化藥物開發的藥理學進步,成為該市場的促進成長因素。
本報告提供全球白血病治療藥市場相關調查,市場概要,以及競爭情形,各市場區隔的市場,各地區分析,及企業簡介等資訊。
Title: Global Leukemia Therapeutic Market Size, Share & Trends Analysis Report by Type (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia) by Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, and Others) ) Forecast 2022-2028.
The global leukemia therapeutic market is anticipated to grow at a substantial CAGR of 7.3% during the forecast period. Acute lymphocytic also known as blood cancer begins from an early version of white blood cells in the bone marrow. The term acute means that leukemia can progress very rapidly, and in case if not treated can be fatal in a few months. Cancer treatments have become advanced day by day, by the use of various therapies the demand and focusing on the unmet medical needs are the prominent factor responsible for the growth of the global leukemia therapeutics market. Moreover, increasing expenditure on research and development, rising focus on the superiority of quality of life, higher investment incurred by the government on healthcare, and advancement in pharmacology to enhance the drug development are factors propelling the growth of this market.
The global leukemia therapeutics market is segmented based on type, and treatment type. Based on type the market is bifurcated into acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia. Based on treatment type, the market is sub-segmented into chemotherapy, immunotherapy, targeted therapy, and others. .
Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America region is anticipated to hold a major share in the global leukemia therapeutics market, due to a large number of patients pool suffering from cancer and the availability of a strong generic drug market in the emerging countries. In addition, manufacturers' interest in expanding to these North American countries, will further fuel the growth in the near future.
The major companies serving the global leukemia therapeutic market are Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb, Cephalon A/S, Daiichi Sankyo, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Novartis, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2021, Novartis announced that the US FDA approved Scemblix(asciminib) for the treatment of chronic myeloid leukemia(CML). The FDA approved this drug for adult patients with Philadelphia chromosome-positive CML in the chronic phase(Ph+CML-CP). Moreover, Scemblix recommends that patients with CML were previously treated with two or more tyrosine kinase inhibitors(TKIs), and reduced mutations at the defective BCR-ABL 1 gene, which is associated with the over-production of leukemic cells.
Research Methodology
The market study of the global leukemia therapeutic market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers: